Trial Search Results

Treatment of Schizoaffective Disorder Using Mifepristone

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Pritzker Family Foundation

Stanford Investigator(s):


  • Drug: Mifepristone
  • Drug: Placebo Oral Tablet


Phase 2/Phase 3


Inclusion Criteria:The subjects will be 30 inpatients or outpatients with schizoaffective
disorder. Exclusion Criteria:Subjects must be between the ages of eighteen and seventy-five
without major medical problems.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jessica Hawkins